

Title (en)  
DENDRITIC CELL TUMOR INJECTION THERAPY AND RELATED VACCINE

Title (de)  
TUMORBEHANDLUNG DURCH INJEKTION VON DENDRITISCHEN ZELLEN UND ENTSPRECHENDER IMPFSTOFF

Title (fr)  
THÉRAPIE PAR INJECTION DANS DES TUMEURS DES CELLULES DENDRITIQUES ET VACCIN ASSOCIÉ

Publication  
**EP 2091334 A4 20100203 (EN)**

Application  
**EP 07871309 A 20071031**

Priority  
• US 2007083161 W 20071031  
• US 85590506 P 20061031

Abstract (en)  
[origin: WO2008063837A2] The present invention provides effective, safe, comprehensive combinatorial treatment methods that are safe and effective for reducing the size of tumor cells in tumor tissue of a patient. The methods include reducing the size of tumor cells in tumor tissue of a patient by collecting monocyte cells from a patient; culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells; introducing the immature dendritic cells and an adjuvant into the tumor tissue of the patient; and introducing activated T cells into the tumor tissue of the patient. The methods further comprise pretreating a patient with local chemotherapy, systemic chemotherapy, tumor irradiation or systemic chemotherapy in combination with local tumor irradiation prior to introducing the immature dendritic cells, adjuvant and activated T cells into the tumor tissue of the patient. Also provided is a cancer vaccine for reducing the size of a tumor in a patient, comprised of immature dendritic cells derived from monocytes collected from the patient, an adjuvant, tumor antigens from the patient, and activated T cells.

IPC 8 full level  
**A01N 63/00** (2006.01); **A61K 39/00** (2006.01); **C12N 5/0783** (2010.01); **C12N 5/0786** (2010.01); **A61K 35/12** (2015.01)

CPC (source: EP US)  
**A61K 39/0011** (2013.01 - US); **A61K 39/4611** (2023.05 - EP); **A61K 39/4615** (2023.05 - EP); **A61K 39/4622** (2023.05 - EP); **A61K 39/464482** (2023.05 - EP); **A61P 35/00** (2018.01 - EP); **C12N 5/0636** (2013.01 - EP); **C12N 5/0639** (2013.01 - EP); **A61K 35/12** (2013.01 - EP); **A61K 2035/124** (2013.01 - EP); **A61K 2039/515** (2013.01 - EP); **A61K 2039/55516** (2013.01 - EP); **A61K 2039/55583** (2013.01 - EP); **A61K 2039/55588** (2013.01 - EP); **A61K 2039/6081** (2013.01 - EP); **A61K 2239/31** (2023.05 - EP); **A61K 2239/38** (2023.05 - EP); **C12N 2501/22** (2013.01 - EP); **C12N 2501/23** (2013.01 - EP); **C12N 2501/515** (2013.01 - EP); **C12N 2501/999** (2013.01 - EP)

Citation (search report)  
• [X] MORISAKI TAKASHI ET AL: "Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.", HUMAN CELL : OFFICIAL JOURNAL OF HUMAN CELL RESEARCH SOCIETY DEC 2003, vol. 16, no. 4, December 2003 (2003-12-01), pages 175 - 182, XP009063515, ISSN: 0914-7470  
• [X] MORISAKI T ET AL: "COMBINED IMMUNOTHERAPY WITH INTRACAVITAL INJECTION OF ACTIVATED LYMPHOCYTES, MONOCYTE-DERIVED DENDRITIC CELLS AND LOW-DOSE OK-432 IN PATIENTS WITH MALIGNANT EFFUSION", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6A, 1 November 2003 (2003-11-01), pages 4459 - 4466, XP009063436, ISSN: 0250-7005  
• [X] KATANO MITSUO ET AL: "Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 25, no. 6A, 1 November 2005 (2005-11-01), pages 3771 - 3776, XP009127019, ISSN: 0250-7005  
• [X] SATO TAKAMI ET AL: "Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: A new approach to cancer immunotherapy.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 53, no. 1, January 2004 (2004-01-01), pages 53 - 61, XP002560230, ISSN: 0340-7004  
• [Y] YU BIN ET AL: "Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 285 - 294, XP002425821, ISSN: 1078-0432  
• [Y] HATFIELD P ET AL: "Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?", CLINICAL ONCOLOGY, W.B. SAUNDERS, vol. 17, no. 1, 1 February 2005 (2005-02-01), pages 1 - 11, XP004693844, ISSN: 0936-6555  
• [Y] YANO YUTARO ET AL: "A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: Efficient maturation of DCs by co-culture with LAK cells in vitro", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 16, no. 1, 1 July 2006 (2006-07-01), pages 147 - 152, XP009127013  
• [T] MANN DEAN L ET AL: "Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES SEP 2009, vol. 1174, September 2009 (2009-09-01), pages 41 - 50, XP002559589, ISSN: 1749-6632

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2008063837 A2 20080529; WO 2008063837 A3 20080918; WO 2008063837 A9 20080807; EP 2091334 A2 20090826; EP 2091334 A4 20100203; JP 2010508364 A 20100318**

DOCDB simple family (application)  
**US 2007083161 W 20071031; EP 07871309 A 20071031; JP 2009535441 A 20071031**